{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 17 of 115', 'Product Status', 'Model', 'Geography', 'Manufacturer', 'Component', 'Number', '2AF234', 'US (investigational)', 'Medtronic,', 'Arctic Front', 'Japan (investigational)', 'Inc.', '2AF284', 'Advance Cardiac', 'CryoAblation', '2AF233', 'Catheter', 'Canada (non-investigational)', 'Medtronic,', 'Europe (non-investigational)', 'Inc.', '2AF283', '239F3', 'US (investigational)', 'Medtronic,', 'Freezor MAX', 'Japan (investigational)', 'Inc.', '239F5', 'Cardiac', '209F3', 'CryoAblation', 'Catheter', 'Canada (non-investigational)', 'Medtronic,', '209F5', 'Europe (non-investigational)', 'Inc.', '990063-020', '1.', 'Demonstrate an acceptable efficacy success rate at 12 months after the', 'Primary Objectives', 'pulmonary vein isolation (PVI) ablation procedure.', '2.', 'Demonstrate an acceptable safety profile of the pulmonary vein isolation (PVI)', 'ablation procedure.', '1.', 'Demonstrate an improvement in quality of life between baseline and 12 months', 'Secondary', 'as measured by the Atrial Fibrillation Effect on QualiTy-of-life Questionnaire', 'Objective', '(AFEQT) and Medical Outcome Study Short Form-12 (SF-12) questionnaires', 'Ancillary', 'Objectives', 'Study Design', 'The study is prospective, interventional, multi-center, non-randomized, single arm,', 'unblinded clinical study. The study will be conducted at up to 25 centers located in', 'the US, Canada, Europe and Japan. The study objectives will be analyzed for a', 'Premarket Approval Supplement (PMA-S) after all subjects from the US, Canada and', 'Europe complete 12 months of follow-up after the index ablation procedure.', 'Study data from the Japanese centers will not be included in the PMA-S submission,', 'but will be included in a submission to Japan Pharmaceuticals and Medical Device', 'Agency (PMDA).', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 18 of 115', 'The Japanese subjects are required by PMDA to support an expanded indication to', 'the persistent AF population in Japan. The PMDA cohort will be analyzed separate to', 'the PMA-S because participation and enrollment in Japan is anticipated to start later', 'than the rest of the PMA-S cohort.', 'Sample Size and', 'Up to 225 subjects will be enrolled world-wide. In the US, Canada and Europe, up to', 'Analysis Timing', '200 subjects will be enrolled to ensure 150 subjects are treated with an Arctic Front', 'Advance Cardiac CryoAblation Catheter. The maximum number of subjects treated', 'at Canadian and European centers combined is 45 subjects.', 'Up to 25 subjects will be enrolled in Japan to ensure 15 subjects are treated with an', 'Arctic Front Advance Cardiac CryoAblation Catheter.', 'At the completion the last 12 month visit from the 150 enrolled and treated subjects', 'from the US, Canada and Europe, a PMA-S will be submitted to the FDA. Study data', 'from the Japanese centers will not be included in the PMA-S submission but will be', 'made available.', 'A final report will be submitted to Japan PMDA at the completion of the last 12 month', 'visit from the 15 treated Japanese subjects. Study data from all 165 treated subjects', 'will be included in this report.', 'Inclusion Criteria', 'Inclusion/Exclusion', 'Documentation of symptomatic persistent AF', 'Criteria', 'Defined as having a continuous episode lasting longer than 7 days but', 'less than 6 months documented by consecutive ECG recordings', 'Failure or intolerance of at least one Class I or III antiarrhythmic drug', 'Age 18 (or older if required by local law) to 80', 'Exclusion Criteria', 'Left atrial diameter > 5.0 cm (anteroposterior)', 'Prior left atrial ablation or surgical procedure (including left atrial appendage', 'closures)', 'Presence or likely implant of a permanent pacemaker, biventricular pacemaker,', 'loop recorder, or any type of implantable cardiac defibrillator (with or without', 'biventricular pacing function) within 12 months', 'Body mass index (BMI) >34', 'Presence of any pulmonary vein stents', 'Presence of any pre-existing pulmonary vein stenosis', 'Pre-existing hemidiaphragmatic paralysis', 'Presence of any cardiac valve prosthesis', 'Moderate or severe mitral valve regurgitation or stenosis', 'Any cardiac surgery, myocardial infarction, PCI/PTCA or coronary artery', 'stenting which occurred during the 3 month interval preceding the consent date', 'Unstable angina', 'NYHA Class IV congestive heart failure and/or documented left ventricular', 'ejection fraction (LVEF) less than 45% measure by acceptable cardiac testing', '(e.g. TTE)', 'Primary pulmonary hypertension', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}